Background: Angiogenesis is key progress in the growth, recurrence, and metastasis of various cancers. Antiangiogenic can improve the blood supply and oxygen content of tumors and enhance the effects of chemotherapy and radiotherapy by normalizing tumor blood vessels and microenvironment. The further recent development of Immune Checkpoint Inhibitors (ICIs) provides significant progress in cancer immunotherapy. The study focused on programmed cell death protein 1 (PD-1) and Cytotoxic T Lymphocyte Antigen 4 (CTLA-4) blockade, reflecting on the evidence of durable responses among various tumor types. The aim of this review is to sum up present evidence and clarify the rationale behind supporting the benefits of combining antiangiogenic with immunotherapy for cancer treatment and list the ongoing clinical trials that are being studied.
Methods: Using PubMed and Web of science, articles published in the whole world have been searched and comprehensively reviewed.
Results: Antiangiogenic agent can trigger antitumor and immunity, and it can also be induced by the immune system. Combining antiangiogenic with immunotherapy may be effective in human cancers.
Conclusion: It is evidenced that combining angiogenesis inhibitors with immunotherapy has a synergistic effect thus improving the curative effect of both agents.